Innate Pharma S.A. (IPHA)

Market Cap	179.27M
Revenue (ttm)	14.84M
Net Income (ttm)	-54.08M
Shares Out	92.16M
EPS (ttm)	-0.64
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	12,664
Open	1.880
Previous Close	1.910
Day's Range	1.880 - 1.960
52-Week Range	1.430 - 3.511
Beta	0.51
Analysts	Strong Buy
Price Target	5.00 (+164.55%)
Earnings Date	Sep 17, 2025

About IPHA

Innate Pharma S.A. operates as a biotechnology company that develops immunotherapies for cancer patients in France and internationally. The company’s products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as ...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Oct 17, 2019
• Employees: 181
• Stock Exchange: NASDAQ
• Ticker Symbol: IPHA
• Website: https://www.innate-pharma.com

Financial Performance

In 2024, Innate Pharma's revenue was 20.12 million, a decrease of -67.36% compared to the previous year's 61.64 million. Losses were -49.47 million, 553.5% more than in 2023.

Financial numbers in EUR

Analyst Forecast

According to 3 analysts, the average rating for IPHA stock is "Strong Buy." The 12-month stock price target is $5.0, which is an increase of 164.55% from the latest price.

Price Target

$5.0

(164.55% upside)

Analyst Consensus: Strong Buy